TerumoTERUMO CORPORATION4543東証プライム精密機器FY ending Mar 2026, consolidated, IFRS
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|---|
| Cardiac and Vascular Company | +15.5%5y | 397,13023.5% | 480,61023.3% | 555,71622.3% | 624,35724.8% | 676,42124.2% |
| Medical Care Solutions Company | +4.2%5y | 185,33512.7% | 191,7497.7% | 197,56910.0% | 211,23510.9% | 216,13810.0% |
| Blood and Cell Technologies Company | +16.1%5y | 120,58617.3% | 147,6057.6% | 168,3289.7% | 200,28013.2% | 231,03714.6% |
| Terumo Organ Technologies | N/A | — | — | — | — | 7,98520.9% |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書-第111期(2025/04/01-2026/03/31)
EDINET (FSA Japan)
有価証券報告書-第110期(2024/04/01-2025/03/31)
EDINET (FSA Japan)
有価証券報告書-第109期(2023/04/01-2024/03/31)
EDINET (FSA Japan)
有価証券報告書-第108期(2022/04/01-2023/03/31)
EDINET (FSA Japan)
訂正有価証券報告書-第107期(令和3年4月1日-令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書-第106期(令和2年4月1日-令和3年3月31日)
Extracted from XBRL: 44 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.